Table 3.
Median and 2-Year PFS and OS in Patients With Methylated Tumors (MGMTav > 0.25) and Unmethylated Tumors (MGMTav ≤ 0.25) in Patients Randomly Assigned to RT and to RT Followed by Adjuvant PCV
| MGMTav | RT |
RT/PCV |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFS |
OS |
PFS |
OS |
|||||||||||||
| Median Duration (months) | 95% CI | 2 Year (%) | 95% CI | Median Duration (months) | 95% CI | 2 Year (%) | 95% CI | Median (months) | 95% CI | 2 Year | 95% CI | Median (months) | 95% CI | 2 Year | 95% CI | |
| ≤ 0.25 | 7.8 | 7.1 to 17.6 | 12.5 | 2.1 to 32.8 | 12.3 | 11.5 to 28.5 | 31.3 | 11.4 to 53.7 | 10.5 | 5.2 to 23.0 | 20.0 | 4.9 to 42.4 | 19.0 | 12.3 to 34.5 | 46.7 | 21.2 to 68.8 |
| > 0.25 | 17.9 | 11.9 to 43.4 | 48.1 | 34.1 to 60.8 | 59.3 | 30.0 to 66.2 | 65.4 | 50.8 to 76.6 | 49.0 | 19.1 to 71.2 | 56.8 | 44.1 to 67.6 | Not reached | Not reached | 71.7 | 59.2 to 81.0 |
Abbreviations: PFS, progression-free survival; OS, overall survival; MGMT, O6-methylguanine-methyltransferase; RT, radiotherapy; PCV, procarbazine, lomustine, and vincristine; av, averaged.